What are the top longevity startups by total funding raised?

Top startups in the Longevity market ranked by total funding raised

Here is an updated table that ranks the top startups in the Longevity market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you need to dig deeper and get more detailed data, please check our report covering the Longevity market.

Which longevity startups have raised the most money?

Altos Labs is still the clear funding outlier in longevity, while Oura, Neko Health, Insilico Medicine and NewLimit form the next group of companies that have attracted unusually large amounts of capital.

Altos launched with $3 billion in committed funding, a figure no other longevity-focused startup has matched. Oura has also moved into billion-dollar cumulative funding territory after several large preferred-stock financings, including a Series E that its current SEC filing shows generated more than $900 million across issuances. Neko Health reached approximately $1 billion of cumulative funding after its huge Series C this year.

Below those three, the gap narrows. Insilico Medicine has accumulated hundreds of millions through private rounds and its Hong Kong IPO. Biosplice Therapeutics, NewLimit and BioAge Labs have also raised several hundred million dollars each.

These companies are barely comparable as businesses today. Altos is funding cellular rejuvenation research. Oura already sells a mass-market wearable and subscription. Neko runs preventive-health clinics. Insilico builds drugs using AI. NewLimit wants to reprogram old cells. The funding ranking increasingly measures several different bets on longer, healthier lives rather than one single longevity industry.

Company	Approx. cumulative funding	Main business
Altos Labs	$3.0B	Cellular rejuvenation
Oura	~$1.6B	Wearables and health intelligence
Neko Health	~$1.0B	Preventive health scanning
Insilico Medicine	~$838M	AI drug discovery
Biosplice Therapeutics	~$778M	Degenerative-disease therapeutics
NewLimit	~$682M	Epigenetic reprogramming
BioAge Labs	~$532M	Aging-biology therapeutics
Celularity	~$398M	Cell therapies
Function Health	~$351M	Preventive testing
UNITY Biotechnology	~$296M	Senolytic therapeutics

How much funding has Altos Labs raised?

Altos Labs has about $3 billion in committed funding, which still puts the cellular-rejuvenation company in a league of its own.

When Altos came out of stealth, the company disclosed roughly $3 billion in committed capital. That was an extraordinary starting position for a biotech company whose core science was still years away from normal commercial validation.

The scale becomes clearer when we compare Altos with other rejuvenation companies. NewLimit has raised roughly $682 million in our reconstruction. Life Biosciences is around $237 million. Retro Biosciences has disclosed at least $180 million. Even when those three are combined, they remain far below Altos.

Altos used that financial head start to build research institutes in the San Francisco Bay Area, San Diego and Cambridge and recruit scientists including several of the best-known names in cellular reprogramming and aging biology.

For now, no other pure longevity biotech has come close to matching Altos on accumulated capital.

Why did Altos Labs get $3 billion before proving its longevity technology in humans?

Altos Labs attracted $3 billion because investors were financing an unusually ambitious research institution rather than a normal biotech built around one or two near-term drug candidates.

Cellular rejuvenation is expensive science. The company has to understand how cells lose function with age, identify ways to alter those processes safely, reproduce the effects across tissues and eventually turn the biology into medicines. Much of that work happens long before a company can generate product revenue.

Altos also assembled an unusually strong scientific roster. The launch organization included figures such as Shinya Yamanaka, whose work on cellular reprogramming won a Nobel Prize, and former GSK research chief Hal Barron. That made the project easier to finance as a long-duration scientific bet.

The $3 billion figure still looks extreme even after several years of stronger longevity fundraising. NewLimit's latest financing shows that investors are now willing to spend hundreds of millions on epigenetic rejuvenation too, but Altos remains the exception rather than the new normal.

How much money has Oura raised?

Oura has now raised well over $1 billion in equity-related financing, and its SEC filings finally give us a much clearer view of how large the company's later rounds became.

The filing shows roughly $199 million of Series D preferred stock issuance and about $907 million of Series E issuance. Within those totals, entities affiliated with Fidelity's parent FMR invested about $125 million in Series D and another $630 million in the Series E in 2025, followed by an additional $10 million investment in early 2026.

Eli Lilly then invested $50 million through a SAFE that converts into Oura shares immediately before the IPO. That was followed by an even bigger development: Oura has now launched its Nasdaq IPO under the ticker OURA.

The proposed offering covers 50 million shares at $40 to $44 each, which creates a headline transaction size of $2.0 billion to $2.2 billion. Most of those shares belong to existing shareholders, however. Oura itself is offering 13.5 million shares and estimates about $533 million of net proceeds at the midpoint of the proposed range.

That distinction is worth keeping. A multibillion-dollar IPO does not mean Oura is raising another $2 billion for the company.

Does Oura still count as a longevity startup now that it is heading to the stock market?

Oura still fits naturally into the modern longevity market because the company is built around continuously measuring sleep, recovery, cardiovascular signals and other health data that people use to manage long-term health.

Oura works very differently from Altos Labs or NewLimit. It does not try to rejuvenate cells or develop a drug against aging biology. Its role sits earlier in the health cycle: measure the body continuously, identify changes and help users adjust behavior or connect those measurements with medical care.

That broader definition increasingly matches where the money is going. Neko Health scans apparently healthy people for early problems. Function Health repeatedly tests biomarkers. Oura collects physiological data every day.

The current IPO makes Oura especially important for the category because investors will soon be able to value a large preventive-health and longevity-adjacent company in the public market rather than through occasional private rounds.

How much funding has Neko Health raised?

Neko Health has raised roughly $1 billion after closing a $700 million Series C, making it one of the best-funded preventive-health companies anywhere in the longevity market.

The recent round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with Atomico, General Catalyst, Lakestar and several other investors participating.

What makes the size of the financing easier to understand is the amount of real demand Neko can already show. The company says more than 100,000 people in Sweden and the UK have completed a Neko scan, while more than 350,000 people have joined its waitlist or registered. Around 75% of members book and prepay for another scan after their first appointment.

Neko has also started expanding into the United States. Its first New York clinic opened with around 25,000 people already waiting locally.

Those numbers give investors something most experimental longevity biotechs cannot offer yet: actual customer behavior. We still do not know how large Neko can become, but there is already strong evidence that people will pay repeatedly for preventive scans.

What are the biggest recent funding rounds in longevity?

Neko Health, NewLimit and Function Health have produced three of the biggest recent private financings in longevity, and together they raised more than $1.4 billion in those rounds alone.

Neko brought in $700 million. NewLimit raised $435 million. Function Health closed a $298 million Series B. Loyal added another $100 million for canine longevity, while Life Biosciences secured $80 million and Nura Bio completed a $73.8 million Series B.

The mix is more interesting than the raw total. Two of the three largest rounds went to preventive-health businesses that already serve customers. NewLimit received the other huge check to move epigenetic-reprogramming medicines toward human trials.

Further down, capital is still reaching more conventional clinical biotech. Life Biosciences raised money for its first human trial of ER-100, while Nura Bio is funding clinical studies of SARM1 inhibitors for neurodegenerative disease.

Neko's $700 million round is the standout transaction. More broadly, very large longevity rounds are now appearing across diagnostics, consumer health and drug development rather than clustering around one scientific idea.

Company	Recent round	Amount	Main use of capital
Neko Health	Series C	$700M	US expansion and clinic growth
NewLimit	Series C	$435M	Reprogramming medicines and human trials
Function Health	Series B	$298M	Preventive testing and medical intelligence
Loyal	Series C	$100M	Regulatory work and launch preparation
Life Biosciences	Series D	$80M	ER-100 Phase 1 and platform development
Nura Bio	Series B	$73.8M	SARM1 clinical programs
Juvenescence	Series B-1 first close	$76M	Longevity therapeutics pipeline
SciNeuro Pharmaceuticals	Equity financing	$53M	Neurodegeneration programs

How much funding has NewLimit raised?

NewLimit has raised roughly $682 million and is currently one of the best-funded private companies trying to turn epigenetic rejuvenation into medicine.

Its latest $435 million Series C was led by Founders Fund, with Thrive Capital, Greenoaks, Quiet Capital and existing investors also participating. NewLimit says the financing will help bring its first aging-reprogramming medicine into human trials.

The pace of fundraising has been unusually fast. Before the Series C, NewLimit had raised a $130 million Series B and then another $45 million from investors including Eli Lilly, Duke Management and Section 32.

That sequence puts NewLimit much closer to Altos in financial ambition than most early rejuvenation startups, even though Altos still has several times more capital.

The next test is harder than raising money. NewLimit says it plans to move its first reprogramming medicine into human clinical trials, which will start showing whether the company's cell-aging results can translate beyond laboratory models.

How much funding has Function Health raised?

Function Health has raised about $351 million, including a $298 million Series B that valued the preventive-health company at $2.5 billion.

Redpoint Ventures led the round, with Andreessen Horowitz, Battery Ventures and other investors participating. The size is striking for a company that began by selling memberships built around repeated laboratory testing.

Function now combines blood testing, health records and other medical data, and it expanded into imaging by acquiring Ezra. The basic pitch is easy to understand: test people much more deeply before they become obviously sick, then keep building a longitudinal picture of their health.

That model has attracted capital very quickly. Function raised nearly six times more in its Series B than the roughly $53 million it had accumulated beforehand.

These days, a longevity company does not need an anti-aging drug to raise biotech-sized rounds. Function is one of the clearest examples.

Are preventive-health startups now raising as much money as anti-aging biotech companies?

Preventive-health startups are now competing with longevity biotech for very large funding rounds, and the gap between the two categories has narrowed sharply.

Neko Health and Function Health recently raised almost $1 billion between them. Oura has accumulated more than $1 billion across its preferred-stock financings and is now going public. Viome added a $25 million Series D to expand its diagnostics business.

Those companies make money much earlier than a drug developer can. Oura sells hardware and subscriptions. Neko sells scans. Function sells testing memberships. Viome sells testing and personalized health products.

Rejuvenation biotech still attracts enormous amounts of capital. Altos remains the largest-funded company in the whole ranking, NewLimit has raised hundreds of millions, and Life Biosciences is now testing partial epigenetic reprogramming in humans.

What has changed is the funding mix. Investors can now choose between trying to alter aging biology and building businesses that measure health deterioration earlier. Both approaches are receiving serious capital.

How much funding has Insilico Medicine raised?

Insilico Medicine has accumulated hundreds of millions of dollars across private funding and its Hong Kong IPO, putting the AI drug-discovery company among the best-funded businesses in the broader longevity market.

The company's public listing added roughly $293 million in gross proceeds based on the final Hong Kong offering documentation.

Insilico is a useful edge case for any longevity ranking. The company came out of aging and longevity research, but today its business is much broader: it uses generative AI and biological data to identify drug targets and design molecules across multiple disease areas.

That broader platform has helped Insilico attract investors that would not necessarily finance a pure anti-aging company. Its backers have included major institutional and strategic names, while the IPO gave it access to public capital as well.

Insilico shows how some longevity startups can grow out of the label. The company may have started close to aging research, but its financing case today rests on whether AI can make drug discovery faster and more productive across medicine.

Which longevity startups are already public or trying to go public?

BioAge Labs, Celularity, UNITY Biotechnology and Insilico Medicine are already publicly traded, while Oura is currently in the middle of its IPO process.

The public-market group covers very different businesses. BioAge develops drugs against pathways linked to aging and metabolic disease. UNITY has worked on senolytic and age-related disease therapeutics. Celularity develops placenta-derived cell therapies and biomaterials. Insilico is an AI-driven drug-discovery company.

Oura will add a very different type of company if the offering completes. Its SEC prospectus describes a large consumer health platform with hardware, subscriptions and partnerships rather than an early clinical biotech.

Public status also changes what "funding raised" means. Private companies usually have identifiable venture rounds. Public companies can raise equity repeatedly through IPOs, follow-on offerings and private placements.

That is why cumulative startup funding becomes less useful once a company spends years on the stock market. We keep the original fundraising history relevant, but current public financing needs to be separated from the venture rounds that built the company.

How much money has BioAge Labs raised?

BioAge Labs has raised more than $500 million when its private financing, IPO and concurrent private placement are considered together.

The most transparent part of that history comes from SEC filings. BioAge completed its IPO at $18 per share, issuing 11 million shares and receiving about $179.6 million in net proceeds. A concurrent private placement with Sofinnova generated another roughly $9.9 million net.

The company is particularly relevant to longevity because it tries to identify drug targets from human aging biology rather than treating aging as a single disease. Its work has increasingly focused on metabolic disease and obesity.

BioAge also shows why big funding totals should never be read as a straight measure of scientific success. Its lead azelaprag program suffered a major setback after the company discontinued development following clinical data.

Capital gives a biotech more chances to recover from failures, but drug development can still erase years of work very quickly.

Why is Biosplice Therapeutics still one of the most-funded longevity companies?

Biosplice Therapeutics remains near the top of cumulative longevity funding because the company raised very large amounts of private capital years before today's longevity boom.

One clearly documented example is its $120 million equity financing in 2021. Eventide Asset Management, aMoon, SymBiosis II, Sands Capital and Verition participated in that round, which was intended to advance programs in osteoarthritis, oncology and neurology.

Biosplice sits at the edge of the longevity definition. Its business is based on alternative pre-mRNA splicing and degenerative disease rather than an explicit promise to extend human lifespan.

That is still relevant to the market because a large part of longevity biotech has moved toward treating specific diseases of aging. Companies have found it far easier to build clinical programs around osteoarthritis, neurodegeneration, metabolic disease or vision loss than around "aging" as one broad regulatory indication.

Biosplice also reminds us that cumulative funding rewards history. A company can stay high in the ranking even when newer companies are currently raising money much faster.

Which cellular-rejuvenation startups have raised the most money?

Altos Labs, NewLimit, Life Biosciences and Retro Biosciences currently form the best-funded group of companies focused directly on cellular or epigenetic rejuvenation.

Altos dominates with its $3 billion capital base. NewLimit follows far behind but has already accumulated roughly $682 million. Life Biosciences has raised around $237 million in our reconstruction, while Retro has disclosed at least $180 million and recently completed another financing whose full size was not announced.

The science differs from company to company. NewLimit is designing epigenetic-reprogramming medicines. Life Biosciences uses partial epigenetic reprogramming and has moved ER-100 into a Phase 1 study for optic neuropathies. Retro runs a broader portfolio covering cellular reprogramming, cell therapy and other aging mechanisms.

The big change is clinical movement. Rejuvenation used to be funded almost entirely on animal studies and laboratory biology. Life Biosciences has now dosed its first patient, while Retro says its first candidate has entered human testing. NewLimit is preparing to follow.

Company	Approx. funding	Approach	Current stage
Altos Labs	$3.0B	Cellular rejuvenation programming	Research and drug development
NewLimit	~$682M	Epigenetic reprogramming	Preparing for human trials
Life Biosciences	~$237M	Partial epigenetic reprogramming	Phase 1
Retro Biosciences	≥$180M	Reprogramming and aging therapeutics	First candidate in humans
Cambrian Bio	~$183M	Aging-biology therapeutics	Portfolio model
Turn Biotechnologies	~$29M	mRNA rejuvenation	Preclinical
Shift Bioscience	~$18M	AI-designed rejuvenation	Early stage
clock.bio	~$9M	Rejuvenation target discovery	Early stage

Is Retro Biosciences becoming a major longevity startup?

Retro Biosciences has become a major longevity company despite raising far less disclosed capital than Altos or NewLimit because investors are now attaching a much higher value to its clinical progress.

Retro announced the initial close of a new financing at a $1.8 billion pre-money valuation, led by 4P Capital. The company did not disclose the size of that round, so adding a guessed amount to cumulative funding would give the ranking false precision.

The operational update behind the financing is more useful. Retro says it moved from its first laboratory to a clinical candidate in three years and took RTR242 from indication selection to first-in-human dosing in roughly 15 months.

That gives Retro a different profile from a company still proving its science only in cells or animals. Human dosing does not prove the drug works, but it removes one layer of uncertainty.

Retro is a good example of why funding rank and company importance sometimes diverge. A startup does not have to be top five in cumulative capital to become one of the companies investors watch most closely.

Is dog longevity really attracting serious venture capital?

Loyal has made dog longevity a serious venture-backed category, with around $252 million of cumulative funding and a recent $100 million Series C.

The company is developing drugs intended to extend healthy lifespan in dogs, with LOY-002 aimed at senior animals. The Series C, led by age1 with participation from Baillie Gifford and existing investors, is financing final regulatory work and preparation for a possible commercial launch.

Loyal's regulatory progress has continued since the round. The company has now received a third Reasonable Expectation of Effectiveness acceptance from the FDA for its canine lifespan-extension program.

Dogs give longevity researchers one practical advantage that human studies cannot easily match: they age much faster. Loyal can therefore run lifespan-related studies over a period that is compatible with venture financing and drug development.

The category is still small, but Loyal has already raised more money than many human longevity biotechs. That would have sounded implausible only a few years ago.

Who are the biggest investors in longevity startups?

There is no single investor controlling longevity funding today; the largest rounds are being financed by a mix of biotech specialists, technology funds, growth investors, pharmaceutical companies and billionaire-backed capital.

ARCH Venture Partners appears across companies including Altos Labs, UNITY Biotechnology and SciNeuro. Founders Fund led NewLimit's latest round. Redpoint led Function Health's Series B. Lightspeed led Neko Health's Series C. Khosla Ventures has backed companies including Viome and Rubedo Life Sciences.

Generalist growth capital has become much more visible too. Thrive Capital and Greenoaks participated in NewLimit. Baillie Gifford invested in Loyal. Fidelity-linked entities put hundreds of millions into Oura before its IPO.

Then there is strategic money. Eli Lilly has invested in Oura and NewLimit, while Sanofi Ventures participated in Nura Bio. M42 led Juvenescence's $76 million Series B-1 first close.

The investor base is broader now than the small group of specialist longevity funds that helped build the sector. That widening pool of capital is one reason individual rounds have become so much larger.

Are big pharmaceutical companies actually investing in longevity?

Large pharmaceutical companies are moving into longevity selectively, especially where the science overlaps with conventional drug development, metabolic health or health data.

Eli Lilly is the clearest current example. The company invested $50 million in Oura through a SAFE, has backed NewLimit, and has also built a commercial relationship with Oura through LillyDirect. Oura's IPO filing says Lilly has indicated interest in buying up to another $100 million of shares in the offering.

Sanofi Ventures participated in Nura Bio's recent Series B. Other pharmaceutical and healthcare groups appear across aging-related drug discovery, neurodegeneration and regenerative medicine.

The pattern is fairly specific. Big pharma is showing interest when a longevity company has a recognizable therapeutic target, clinical program, data platform or connection to an existing treatment market.

There is much less evidence of pharmaceutical companies writing giant checks simply for a general promise to make humans live longer. The money tends to follow something that can eventually fit into normal healthcare.

Which kinds of longevity startups attract the most funding?

Drug developers still account for a huge share of longevity funding, but preventive-health companies have become the strongest competing business model.

Altos, NewLimit, BioAge, Biosplice, UNITY, Life Biosciences, Retro and other therapeutics companies have collectively absorbed billions of dollars. Drug development remains the place where investors will tolerate long periods without revenue if the potential medical payoff is large enough.

Preventive health offers a very different route. Oura can sell a ring immediately. Neko can charge for a scan. Function can sell annual testing memberships. These companies can show revenue, repeat purchases and customer demand years before a novel drug would normally reach the market.

AI drug discovery forms another category. Insilico Medicine can use the same underlying platform across many disease programs, which makes its value less dependent on one longevity drug working.

Today's funding market therefore favors three broad models: companies trying to change aging biology, companies trying to measure health decline earlier, and technology platforms that help discover treatments faster.

How concentrated is longevity startup funding?

Longevity funding is heavily concentrated, with a handful of companies absorbing a large share of all the capital raised by the top of the market.

Using the reconstructed totals in the ranking, Altos alone represents roughly a quarter of the money held by the top group. Adding Oura and Neko pushes the first three companies close to half of the capital represented by the top 20.

The drop-off is steep. Companies around the bottom of the top 20 generally sit in the $150 million to $250 million range. Move further down the ranking and many startups have raised less than $50 million.

So a count of funded longevity startups can make the sector look more evenly financed than it really is. Dozens of companies exist, but only a small number have been given enough capital to run several expensive programs, build international consumer infrastructure or survive repeated clinical failures.

Funding group	Approximate share of top funding
Altos Labs alone	About one-quarter
Top 3 companies	Close to one-half
Top 5 companies	Roughly three-fifths
Top 10 companies	Around four-fifths
Companies ranked 11–20	Roughly one-fifth
Companies below the top 20	Much smaller individual funding bases
Typical startup around ranks 50–70	Usually tens of millions, not hundreds

Are $100 million longevity funding rounds becoming normal?

A $100 million longevity round is no longer shocking, although it is still far from normal for the average company in the market.

The clearest change is frequency. Loyal raised exactly $100 million. Life Biosciences came close at $80 million. Nura Bio raised nearly $74 million. Those would already be large rounds in many biotech niches.

At the upper end, the numbers have moved into a completely different range. Neko, NewLimit and Function have recently completed rounds running from almost $300 million to $700 million.

Those checks tend to appear when investors can see a credible path to scale. Neko has repeat customers and international clinic demand. Function has built a fast-growing preventive-health membership. Loyal has regulatory milestones. NewLimit has a defined path toward human trials.

For an early startup with only promising aging biology, raising $100 million remains difficult. For the small group that can show clinical progress or strong customer adoption, nine-figure rounds have become much more plausible.

Does raising more money mean a longevity startup is more likely to succeed?

A bigger funding total gives a longevity startup more room to experiment and survive setbacks, but it tells us surprisingly little about whether the science or business will ultimately work.

BioAge is a useful warning. The company successfully reached the public market and built a large cash position, then discontinued its azelaprag program after clinical results changed the development case.

Altos presents the opposite uncertainty at a much larger scale. Its $3 billion capital base lets the company hire exceptional scientists and explore several approaches at once, but the amount invested cannot tell us whether cellular rejuvenation will eventually become safe, effective medicine.

Clinical progress can sometimes tell us more than cumulative fundraising. Life Biosciences has started dosing patients with ER-100. Retro has moved its first candidate into humans. Loyal has accumulated multiple FDA regulatory acceptances. Neko can point to repeat customers rather than laboratory milestones.

Funding measures how much belief and financial runway a company has accumulated. Once the money is raised, the evidence that matters begins to change.

Is longevity funding moving away from anti-aging drugs?

Longevity funding is broadening beyond anti-aging drugs, but investors have clearly not abandoned rejuvenation biotechnology.

Preventive health has taken a much larger share of attention lately. Oura is heading to the public market. Neko has expanded from Sweden and the UK into New York. Function raised one of the largest Series B rounds in the category.

At the same time, NewLimit secured one of the largest biotech financings in the market, Life Biosciences moved epigenetic reprogramming into a human study, and Retro raised again at a $1.8 billion pre-money valuation.

The sector now has several ways to attack the same basic problem. Some companies want to detect disease earlier. Others want to track physiological change continuously. A smaller but heavily financed group is trying to modify the biology of aging itself.

That wider definition is probably here to stay. "Longevity" has become a useful umbrella for businesses that intervene at very different points between healthy adulthood and age-related disease.

What does the funding ranking tell us about the longevity market right now?

The longevity market has become a serious multibillion-dollar funding category, but most of the money is concentrated in a few companies pursuing very different versions of healthier aging.

Altos still defines the extreme end of scientific ambition with its $3 billion capital base. Oura shows that health monitoring can grow into a public-market-scale business. Neko and Function show how quickly investors are funding preventive diagnostics. NewLimit, Life Biosciences and Retro keep direct cellular rejuvenation firmly in the picture.

The strongest recent change is the variety of companies receiving large checks. Five years ago, the biggest longevity stories were mainly speculative biotechnology projects. Today, investors can choose between a smart-ring company with millions of users, a chain of preventive-health clinics, laboratory-testing memberships, AI drug discovery, canine longevity and multiple forms of cellular reprogramming.

There is still a huge gap between raising money and extending healthy lifespan. Some companies in this ranking may eventually prove medically important; others will probably disappear despite having raised hundreds of millions.

For now, the funding evidence is clear: longevity has moved well beyond a niche anti-aging trade. Investors are putting serious money into several competing ways of finding disease earlier, treating the diseases of aging and, in the most ambitious programs, trying to change aging biology itself.